Article February 1, 1997

Efficacy of Olanzapine: An Overview of Pivotal Clinical Trials

Charles M. Beasley, Jr., M.D.; Gary D. Tollefson, M.D., Ph.D.; Pierre V. Tran, M.D.

J Clin Psychiatry 1997;58(suppl 10):7-12

Article Abstract

Olanzapine is a new "atypical" antipsychotic agent that belongs chemically to the thienobenzodiazepineclass. Its relatively greater binding affinity for 5-HT2 compared to D2 receptors makes it similarto the atypical agent clozapine, a serotonin/dopamine antagonist. Four double-blind pivotal studies,which compare olanzapine to placebo and/or haloperidol, are presented. The results suggest thatolanzapine is as effective as haloperidol for positive symptoms and more effective than haloperidolfor the treatment of the negative symptoms of schizophrenia.